Loading publications…
The last 5 uploaded publications
612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
R. Lozano Mejorada, E. Castro Marcos, Isabel M. Aragón, Heather Thorne, Fernando López‐Campos, Alejandro Sanz-Carbonell, C. Alonso, Urbano Anido, M.J. Juan Fita, A.M. Gutierrez Pecharromán, M. Backhaus, Judith Balmañà, Isabel Chirivella González, Gemma Llort, Nuria Romero-Laorden, Sara Arévalo Lobera, J. Rubio‐Briones, Colin C. Pritchard, Shahneen Sandhu, David Olmos (2020). 612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study. , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.872.
Article63 days ago644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?
Nuria Romero-Laorden, Casilda Llácer Pérez, E. Castro Marcos, Daniela C. Salles, R. Lozano Mejorada, Heather Thorne, Isabel M. Aragón, Fernando López‐Campos, J. Rubio‐Briones, A.M. Gutierrez Pecharromán, Juan Daniel Prieto Cuadra, M.I. Pacheco, Teresa Garcés, Francisco Zambrana, Joaquı́n Mateo, Pedro P. López‐Casas, Shahneen Sandhu, Emmanuel S. Antonarakis, David Olmos, Tamara L. Lotan (2020). 644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?. , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.903.
Article63 days ago644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?
Nuria Romero-Laorden, Casilda Llácer Pérez, E. Castro Marcos, Daniela C. Salles, R. Lozano Mejorada, Heather Thorne, Isabel M. Aragón, Fernando López‐Campos, J. Rubio‐Briones, A.M. Gutierrez Pecharromán, Juan Daniel Prieto Cuadra, M.I. Pacheco, Teresa Garcés, Francisco Zambrana, Joaquı́n Mateo, Pedro P. López‐Casas, Shahneen Sandhu, Emmanuel S. Antonarakis, David Olmos, Tamara L. Lotan (2020). 644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?. , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.903.
Article63 days ago692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Carlo Cattrini, R. Lozano Mejorada, Vincenza Conteduca, María Dolores Martínez Ruíz, Martijn P. Lolkema, David Lorente, Shahneen Sandhu, Nuria Romero-Laorden, Yohann Loriot, Arun Azad, Luís Costa, Armelle Vinceneux, Ravindran Kanesvaran, Yüksel Ürün, Javier Puente, Gerhardt Attard, N. Mehra, Ugo De Giorgi, David Olmos, E. Castro Marcos (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.2086.
Article63 days agoCirculating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
Shahneen Sandhu, Nuria Romero-Laorden, Ylenia Cendón, Adam Sharp, Enrique de Álava, M.I. Pacheco, Pasquale Rescigno, Casilda Llácer, M.I. Sáez, L. Rivera, Francesca Vitrone, C Puivecino Moreno, Joaquı́n Mateo, Johann S. de Bono, David Olmos, R. Lozano Mejorada, David Lorente, Elena Castro, Diletta Bianchini, Paz Nombela (2019). Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc). , 30, DOI: https://doi.org/10.1093/annonc/mdz248.046.
Article63 days ago